Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.  Bone Marrow Transplantation.  2021
2020 Total body irradiation and risk of breast cancer after blood or marrow transplantation: A blood or marrow transplantation survivor study report.  Journal of Clinical Oncology.  38:2872-2882. 2020
2019 Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia.  Histopathology.  75:185-192. 2019
2019 Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.  Biology of Blood and Marrow Transplantation.  25:233-238. 2019
2018 Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.  JAMA Oncology.  4. 2018
2018 Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.  Leukemia.  32:2706-2709. 2018
2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.  Bone Marrow Transplantation.  53:1345-1348. 2018
2018 Two cases and a review of graft-versus-host disease and the role of hepatitis C treatment in liver transplant patients 2018
2018 Late mortality after autologous blood or marrow transplantation in childhood: A Blood or Marrow Transplant Survivor Study-2 report.  Blood.  131:2720-2729. 2018
2017 Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure.  Bone Marrow Transplantation.  52:157-158. 2017
2016 In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia.  PLoS ONE.  11. 2016
2016 Acute myofascitis as a manifestation of chronic graft-versus-host disease.  Muscle and Nerve.  53:327-329. 2016
2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features.  Cancer Causes and Control.  27:81-91. 2016
2012 How we closed the gap between red blood cell utilization and whole blood collections in our institution.  Transfusion.  52:1857-1867. 2012
2012 Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients.  Supportive Care in Cancer.  20:1405-1415. 2012
2007 Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation 2007
2006 Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: Determination of the best diagnostic approach.  Bone Marrow Transplantation.  38:371-376. 2006
2006 Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen.  Biology of Blood and Marrow Transplantation.  12:770-777. 2006
2006 High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up.  Neuro-Oncology.  8:183-188. 2006
2004 Adoptive Immunotherapy with Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes for Recurrent, EBV-Positive Hodgkin Disease.  Cancer.  100:1892-1901. 2004
2003 High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.  Journal of Neuro-Oncology.  65:127-134. 2003
2002 Fungal brain abscess in transplant recipients: Epidemiologic, microbiologic, and clinical features.  Clinical Transplantation.  16:419-424. 2002
2002 A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.  Biology of Blood and Marrow Transplantation.  8:619-624. 2002
2001 Fatal sickle cell crisis after granulocyte colony-stimulating factor administration [1].  Blood.  97:3313-3314. 2001
2001 Invasive mold infections in allogeneic bone marrow transplant recipients.  Clinical Infectious Diseases.  32:1319-1324. 2001
2000 Adoptive immunotherapy with allogeneic EBV CTL for organ transplant patients with ebv induced lymphoproliferative disease.  Blood.  96. 2000
2000 Diagnosis of gastrointestinal graft-versus-host disease.  American Journal of Gastroenterology.  95:3034-3038. 2000
2000 A phase I-II trial to examine the toxicity of CMV- and EVB-specific cytotoxic T lymphocytes when used for prophylaxis against EVB and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.  Human Gene Therapy.  11:1453-1463. 2000
2000 Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.  Neuro-Oncology.  2:114-119. 2000
1997 Bone marrow transplantation for non-Hodgkin's lymphoma: A review.  American Journal of the Medical Sciences.  313:228-235. 1997
1996 Malignancy-associated pulmonary veno-occlusive disease: Report of a case following autologous bone marrow transplantation and review.  Bone Marrow Transplantation.  18:755-760. 1996
1995 Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.  Bone Marrow Transplantation.  16:353-358. 1995
1994 Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.  Journal of Clinical Oncology.  12:1890-1901. 1994
1993 A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.  Investigational New Drugs.  11:169-179. 1993
1993 Durable complete remission in a patient with refractory mediastinal non-seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation.  Bone Marrow Transplantation.  12:541-546. 1993
1993 Immunotoxins for the therapy of graft versus host disease..  Cancer Treatment and Research.  68:133-144. 1993

Principal Investigator On

  • Private Grant  awarded by Merck, Sharp, and Dohme (MSD) Research Foundation 2011 - 2016
  • Private Grant  awarded by CHIMERIX, INC. 2010 - 2012

    • Investigator On

  • BMT CTN 1703/1801 A Randomized, Multicenter Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non Myeloablative / Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation and Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)  awarded by National Marrow Donor Program 2019 - 2025
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2020 - 2025
  • Private Grant  awarded by AMGEN, INC.^ 2020 - 2024
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC. 2021 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • Private Grant  awarded by MARKER THERAPEUTICS INC 2021 - 2024
  • Private Grant  awarded by ONCOIMMUNE, INC. 2020 - 2023
  • Private Grant  awarded by MUNDIPHARMA 2018 - 2023
  • Private Grant  awarded by BLUEBIRD BIO INC. 2020 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC. 2019 - 2022
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program 2017 - 2022
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2017 - 2021
  • A Randomized Phase III Study Comparing Conventional Dose Treatment using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)  awarded by Dana-Farber Cancer Institute 2013 - 2021
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2021
  • High VS. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients  awarded by VANDERBILT UNIVERSITY 2017 - 2021
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  awarded by National Marrow Donor Program 2017 - 2019
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC. 2013 - 2018
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2014 - 2018
  • Multi-center, Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) Regimen  awarded by University of Michigan 2012 - 2016
  • A Genome-Wide Methylation Study of Epigenetic Contributions to Multiple Myeloma  awarded by National Cancer Institute/NIH/DHHS 2011 - 2015
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University 2014 - 2015

    • Education And Training

  • Doctor of Medicine, Louisiana State University System : University of New Orleans 1986
  • Charity Hospital of New Orleans, Internship 1987
  • Charity Hospital of New Orleans, Residency 1989
  • University of Texas Health Science Center, Postdoctoral Fellowship 1993
  • Charity Hospital of New Orleans, Postdoctoral Fellowship 1990

    • Full Name

  • Donna Salzman